J&J’s Doribax Is Subject Of FDA’s First “Complete Response” For An NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
End of FDA’s “approvable” and “not approvable” era means less guidance for determining the prospects for an application after an initial rejection.
You may also be interested in...
‘Structured’ Takeover: A Bitter Pill That More Will Swallow Gladly
Delayed-reward setup gives pharma the edge, but can hold advantages for acquisition targets, panel says.
‘Structured’ Takeover: A Bitter Pill That More Will Swallow Gladly
Delayed-reward setup gives pharma the edge, but can hold advantages for acquisition targets, panel says.
Dalbavancin Delay: Pfizer Pulls NDA To Conduct Extra Phase III Trial
Additional study for the antibiotic will take 18 months to complete, company says